About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lucid Diagnostics Inc. - Common Stock (NQ:LUCD)

1.006 +0.016 (+1.66%)
Streaming Delayed Price Updated: 2:56 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lucid Diagnostics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
From PAVmed Inc.
Via Business Wire
News headline image
Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 11, 2022 ↗
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. 
Via Benzinga
News headline image
Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
From PAVmed Inc.
Via Business Wire
News headline image
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million. 
Via Benzinga
News headline image
Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO
From PAVmed Inc.
Via Business Wire
News headline image
Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
How Is The Market Feeling About Lucid Diagnostics Inc. - Common Stock? ↗
Lucid Diagnostics Inc. - Common Stock's (NASDAQ:LUCD) short percent of float has fallen 4.35% since its last report. The company recently reported that it has 378.70 thousand... 
Via Benzinga
News headline image
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
From PAVmed Inc.
Via Business Wire
News headline image
Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
10 Biggest Price Target Changes For Tuesday ↗
BTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading. 
Via Benzinga
News headline image
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) shares moved upwards by 55.5% to $2.13 during Thursday's pre-market session. The market value of their outstanding... 
Via Benzinga
News headline image
PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
From Lucid Diagnostics Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.